Regeneron’s CLIO-1 Update: What a Completed Early Lymphoma Trial Means for REGN Investors
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Regeneron’s CLIO-1 trial, officially titled “A Phase 1 Study to Assess Safety and Tolerability of Odronextamab (REGN1979)… and Cemiplimab (REGN2810)… in Patients With B-Cell Malignancies,” tests a new drug combo in tough B‑cell lymphomas. The main goal is to find a safe dose and early safety signals, which is important groundwork for any future late-stage programs.
The study uses two antibody drugs: odronextamab, a bispecific that aims to redirect immune cells to attack CD20-positive cancer cells, and cemiplimab, a PD-1 blocker already approved as Libtayo. The pair is designed to boost the body’s own defenses against aggressive B‑cell cancers that have come back or not responded to earlier treatment.
This is an early-stage interventional study with no placebo or randomization, so all patients receive active treatment. It follows a parallel-group, open-label design, meaning doctors and patients know which doses are used, and the main purpose is treatment-focused dose finding rather than direct head‑to‑head comparisons.
The trial was first submitted in January 2016, marking the start of clinical work on the combo strategy. The latest update on June 1, 2026, comes after the study reached “completed” status, signaling that treatment and follow-up are done and the focus shifts to analyzing results and planning next steps.
For investors in REGN, a completed Phase 1 in relapsed B‑cell lymphoma supports the broader oncology pipeline beyond Libtayo’s current uses. Clear safety and a viable dose could justify larger trials and keep Regeneron competitive against other bispecific and checkpoint players like Roche and AbbVie, though near-term revenue effects are limited until later-stage data emerge.
The CLIO-1 study is now completed and recently updated, and further details are available on the ClinicalTrials.gov portal under NCT02651662.
To learn more about REGN’s potential, visit the Regeneron Pharmaceuticals drug pipeline page.
